USP5 and OTUB1 stabilize c-Maf and promote myeloma cell proliferation and survival [140–143], which indicates that USP5/c-Maf or OTUB1/c-Maf axis could be a potential target for myeloma therapy. Here, MAF is linked to plasma cell myeloma.